NCT05160883 is a clinical trial in Hereditary Ataxia, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT05160883?

NCT05160883 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What condition does NCT05160883 study?

NCT05160883 studies Hereditary Ataxia.

Is NCT05160883 still recruiting?

NCT05160883 is currently status unknown. Last updated 16 December 2021.

Last reviewed 2021-12-16 · How we verify

NCT05160883

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neuroimaging Changes in Hereditary Ataxia

Status unknown Last updated 16 December 2021

What this trial tests

trial in Hereditary Ataxia in 500 participants. Status unknown.

Timeline

30 June 2021

Primary endpoint
25 December 2025

25 December 2025

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	30 June 2021
Primary completion	25 December 2025
Estimated completion	25 December 2025
Sites	1 location across China

Conditions studied

Hereditary Ataxia — all drugs for Hereditary Ataxia →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 65, any sex, with Hereditary Ataxia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aim to investigate the neuroimaging changes of hereditary ataxia patients, especially in the SCA3 patients in preclinical or mild stage.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hereditary Ataxia

Currently open trials in the same condition.

NCT07092358 — Hereditary Ataxia Research on Multi-Omics and Neuroclinical Insights in the Yangtze Delta · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05160883 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 16 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05160883.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing